St. James University Hospital | Oncology Clinical Research Facility

Research site

(Unclaimed)

Location

Street James's University Hospital Beckett Street, Leeds, Leeds, England

Site insights

Top conditions

Top treatments

VX-445

VX-121

Imatinib

Defibrotide

Rucaparib

Cysteamine

Moxifloxacin

Ripretinib

Amoxicillin-clavulanate

Anakinra

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 38 total trials

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...

Active, not recruiting

Cystic Fibrosis

Drug: VX-121/TEZ/D-IVA

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting

FIGO Stage III-IV

Newly Diagnosed

Drug: Placebo Oral Tablet

Drug: Rucaparib

Locations recently updated

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)

This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GI...

Enrolling

GIST

Drug: Sunitinib

Drug: Ripretinib

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting

HER2-Positive Primary Breast Cancer

Residual Invasive Breast Cancer

Drug: DS-8201a

Drug: T-DM1

Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts (PAES)

An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal dise...

Enrolling

Kidney Transplantation in Highly Sensitized Patients

Other: Normal Transplantation Routine

Drug: Imlifidase

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Enrolling

Non-alcoholic Steatohepatitis

Drug: Placebo

Drug: Semaglutide